Jumpkicks Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (25)

Latest Posts

About This Stock More About This Stock
E Finally A Real Cancer Diagnosis Breakthrough?
Article By: Terry Chrisomalis
Friday, May 3, 2019 8:04 AM EDT
TOMDF is a diagnostics company that utilizes blood tests for early detection of cancer and neurodegenerative diseases. But is it a good investment? I took a deeper look and reached out to the company's CEO, Herman Weiss, to get the facts.
In this article: TOMDF, AMBS
Read
Depomed To Acquire U.S. Rights To NUCYNTA®, NUCYNTA® ER; Amgen Presents First-Line Use Of Vectibix®
Article By: BioMedReports
Friday, January 16, 2015 3:44 AM EDT
Depomed Inc. announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion.
In this article: DEPO, AMGN, DDD, ADXS, ALDX, AMBS, AMED, BSDM, BMRN, CBMG, DVCR, GALE, GB, HTBX, HEB, ISRG, OMED, PMCB, PRGB, RGDX, TGTX, WCUI
Read

PARTNER HEADLINES

Latest Tweets for $AMBS

No tweets yet!

$AMBS

Finally A Real Cancer Diagnosis Breakthrough?
Kurt Benson 5/3/2019 1:09:50 PM

Sounds like some big news for #TodosMedical and #AmarantusBiosciences today. Very promising. Can anyone weigh in if this science is as much of a breakthrough in cancer diagnosis as it sounds? $TOMDF $AMBS

1 to 1 of 1 comments